All In Biotech

Drug Trial Radar · NCT05856760

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

48

Actual

Start

May 19, 2023

Primary completion

Oct 14, 2024

Study completion Oct 25, 2024

Sponsor

Lead sponsor
Travere Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry

Conditions

  • Immunoglobulin A Nephropathy

Interventions

  • SparsentanDrug

    Target dose of 400 mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24Time frame: Week 24

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • Travere Investigational Site

    Birmingham, Alabama

  • Travere Investigational Site

    Chula Vista, California

  • Travere Investigational Site

    Garden Grove, California

  • Travere Investigational Site

    Glendale, California

  • Travere Investigational Site

    Denver, Colorado

  • Travere Investigational Site

    Boise, Idaho

  • Travere Investigational Site

    Chubbuck, Idaho

  • Travere Investigational Site

    Idaho Falls, Idaho

  • Travere Investigational Site

    Chicago, Illinois

  • Travere Investigational Site

    Evergreen Park, Illinois

  • Travere Investigational Site

    Fort Wayne, Indiana

  • Travere Investigational Site

    Kansas City, Kansas

  • Travere Investigational Site

    Louisville, Kentucky

  • Travere Investigational Site

    Shreveport, Louisiana

  • Travere Investigational Site

    Albuquerque, New Mexico

  • Travere Investigation Site

    Clifton Park, New York

  • Travere Investigational Site

    Fresh Meadows, New York

  • Travere Investigational Site

    New York, New York

  • Travere Investigational Site

    Jacksonville, North Carolina

  • Travere Investigational Site

    New Bern, North Carolina

  • Travere Investigational Site

    Columbus, Ohio

  • Travere Investigational Site

    Philadelphia, Pennsylvania

  • Travere Investigational Site

    Columbia, South Carolina

  • Travere Investigational Site

    Dallas, Texas

  • Travere Investigational Site

    Dallas, Texas

  • Travere Investigational Site

    Hong Kong, Hong Kong

  • Travere Investigational Site

    Kowloon, Hong Kong

  • Travere Investigational Site

    Shatin, Hong Kong

  • Travere Investigational Site

    Sheung Wan, Hong Kong

  • Travere Investigational Site

    Tsuen Wan, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.